Compare Fastly Inc (FSLY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Recursion Pharmaceuticals Inc — how do they compare? Fastly Inc trades at $19.82 (market cap $3.13B), while Recursion Pharmaceuticals Inc trades at $3.06 (market cap $1.75B). The key difference: Fastly Inc is the larger of the two by market cap, and Fastly Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| FSLY | RXRX | |
|---|---|---|
Market Cap | $3.13B | $1.75B |
Sector | Technology | Health |
52-Week High | $33.50 | $6.79 |
52-Week Low | $6.36 | $2.84 |
Enterprise Value | $3.20B | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $20.17, down 3.49% today, with a bullish technical signal from moving averages and a consensus analyst price target of $24.25. The company shows improving revenue growth, reaching $624M in 2025, and has beaten EPS estimates for three consecutive quarters. Recent news highlights partnerships in digital sustainability and edge AI, though the stock faces pressure from negative net income margins and high cash burn.
The outlook is cautiously optimistic, with potential upside from continued execution on AI-driven edge cloud demand and margin expansion. Key risks include persistent profitability challenges, competitive pressures from larger peers, and volatile cash flow trends. Investors should weigh the growth trajectory against fundamental weaknesses before positioning.
Recursion Pharmaceuticals (RXRX) trades at $3.07, down 8.08% in the last session, reflecting ongoing investor concerns about its financial performance. The stock shows a bearish technical signal with moving averages indicating selling pressure, while the company continues to report significant losses with a net income margin of -851.51% for 2025. Recent earnings have consistently beaten expectations, and analyst sentiment remains mixed with a consensus price target of $7.83 representing substantial upside potential from current levels.
The outlook for RXRX hinges on its ability to translate its AI-driven drug discovery platform into sustainable revenue growth and eventual profitability. While the company maintains analyst support and strong institutional backing, significant execution risks remain given its substantial cash burn and negative profitability metrics. The stock presents a high-risk, high-reward opportunity for investors willing to bet on the company's long-term technology potential despite current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
